Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 58.9% from the December 15th total of 799,400 shares. Currently, 7.4% of the shares of the company are short sold. Based on an average trading volume of 171,900 shares, the short-interest ratio is presently 7.4 days.

Telomir Pharmaceuticals Stock Performance

NASDAQ:TELO traded down $0.06 during mid-day trading on Thursday, hitting $4.79. 64,370 shares of the company traded hands, compared to its average volume of 123,466. The stock’s fifty day moving average price is $4.59 and its 200-day moving average price is $4.75. Telomir Pharmaceuticals has a one year low of $3.11 and a one year high of $20.72.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Barclays PLC raised its stake in Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after acquiring an additional 5,367 shares during the period. Beaird Harris Wealth Management LLC raised its stake in Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after purchasing an additional 9,950 shares during the period. State Street Corp boosted its stake in Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after purchasing an additional 17,967 shares during the period. Bank of New York Mellon Corp purchased a new stake in Telomir Pharmaceuticals during the 2nd quarter valued at approximately $241,000. Finally, Suncoast Equity Management raised its position in shares of Telomir Pharmaceuticals by 109.9% during the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after buying an additional 26,803 shares during the last quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.